TRPV1 and steatosis: Four weeks of oral treatment with evodiamine (TRPV1 agonist) induced atheroprotection in ApoE−/− mice, but not in ApoE−/−/TRPV1−/− mice, by alleviating hyperlipidemia and systemic inflammation as well as hepatic macrovesicular steatosis.